There really [isnt] any data out there that specifically link the time spent on GLP-1s on the ability to maintain the weight, she said
Studies show that this class of drugs can be used to treat heart failure, liver disease, anxiety and depression, neurodegenerative disorders, kidney disease, sleep apnea, and addiction disorders
Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019
The STEP 1 clinical trial, published in The New England Journal of Medicine , enrolled nearly 2,000 adults with overweight or obesity and found that participants using semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks
Given the importance of muscle mass in maintaining metabolic health, we examined the impact of GLP-1 analogs on both muscle mass and energy expenditure in this study